论文部分内容阅读
目的探讨个性化循证护理辅助神经节苷脂(GM1)联合纳美芬治疗重症颅脑损伤的临床应用价值。方法将204例重症颅脑损伤患者随机分为研究组与对照组各102例。对照组采用单纯GM1治疗,研究组采用GM1联合纳美芬治疗,所有患者均进行个性化循证护理辅助和基础治疗。比较2组患者伤后6个月的疗效情况及术后并发症发生率。结果研究组的总有效率为91.18%明显高于对照组的83.33%,治疗后研究组患者昏迷发生率为20.59%(21/102)低于对照组的37.25%(38/102),昏迷时间为(11.22±6.31)d短于对照组的(23.51±7.33)d,呼吸道感染、酸碱平衡障碍的发生率明显低于对照组,差异均有统计学意义(P<0.05),2组患者上消化道出血的发生率比较差异无统计学意义(P>0.05)。结论个性化循证护理辅助GM1联合纳美芬治疗重症颅脑损伤疗效确切,安全可靠,值得临床推广应用。
Objective To explore the clinical value of personalized evidence-based care adjuvant ganglioside (GM1) combined with nalmefene in the treatment of severe craniocerebral injury. Methods Totally 204 patients with severe craniocerebral injury were randomly divided into study group and control group with 102 cases each. The control group with simple GM1 treatment, the study group with GM1 combined with nalmefene treatment, all patients were personalized evidence-based nursing and basic treatment. The curative effect of 6 months after operation and the incidence of postoperative complications were compared between the two groups. Results The total effective rate was 91.18% in the study group and 83.33% in the control group. After treatment, the incidence of coma in the study group was 20.59% (21/102), which was lower than 37.25% (38/102) in the control group. The coma time (11.22 ± 6.31) d was shorter than that of the control group (23.51 ± 7.33) d. The incidence of respiratory tract infection and acid-base balance disorder was significantly lower than that of the control group (P <0.05) The incidence of upper gastrointestinal bleeding was no significant difference (P> 0.05). Conclusion The combination of personalized evidence-based nursing with GM1 and nalmefent in the treatment of severe craniocerebral injury is effective, safe and reliable, and is worthy of clinical application.